NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable tumors receive adjuvant endocrine therapy. Patients with metastatic ER+ breast cancer also receive hormone t...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2018-07-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/758 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849699946400317440 |
|---|---|
| author | V. F. Semiglazov V. V. Semiglazov G. A. Dashyan P. V. Krivorotko V. G. Ivanov E. K. Zhiltsova R. M. Paltuev L. M. Bershtein T. Yu. Semiglazova S. S. Yerechshenko V. V. Klimenko V. S. Apollonova A. V. Komyahov A. A. Bessonov |
| author_facet | V. F. Semiglazov V. V. Semiglazov G. A. Dashyan P. V. Krivorotko V. G. Ivanov E. K. Zhiltsova R. M. Paltuev L. M. Bershtein T. Yu. Semiglazova S. S. Yerechshenko V. V. Klimenko V. S. Apollonova A. V. Komyahov A. A. Bessonov |
| author_sort | V. F. Semiglazov |
| collection | DOAJ |
| description | More than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable tumors receive adjuvant endocrine therapy. Patients with metastatic ER+ breast cancer also receive hormone therapy as first-line treatment. Patients with ER+/PR+ locally advanced breast cancer including potentially operable cases (cT2N1, cT3N0M0) are still a subject to neoadjuvant chemotherapy in most of the oncology centers in Russia and worldwide. More than 10 years ago, several trials evaluating the efficacy of neoadjuvant endocrine therapy were conducted in the Petrov Research Institute of Oncology (aromatase inhibitors vs tamoxifen, neoadjuvant endocrine therapy vs neoadjuvant chemotherapy, etc.) The primary endpoint was the evaluation of pathologic complete/partial response to therapy and the frequency of breast-conserving surgeries following neoadjuvant treatment. We now represent 10-year long-term follow-up data on comparison of neoadjuvant chemotherapy with neoadjuvant endocrine therapy after retrospective determination of IHC- phenotypes of 239 patients with ER+ breast cancer. The study results show tendency to better 10-year disease-free survival in patients with luminal-A breast cancer who received endocrine therapy compared to neoadjuvant chemotherapy (72.8 % vs 53.9 %, respectively, p=0.062) There were no statistically significant differences in DFS rates among patients with the luminal B breast cancer subtype (41 % vs 40 %) The discovery of biomarkers of potential resistance to endocrine therapy (cycline-dependant kinase activity [cdk 4/6], estrogenreceptor mutation [ESR1], mTOR signaling pathway activity, co-expression of the ER and HER2neu [ER+/ HER2neu3+]) and ways to inhibit the activity of the resistance pathways (palbocyclib, everolimus, etc.) have expanded the armamentarium of endocrine-therapy for not only metastatic and locally-advanced but also operable cases of ER+ breast cancer. |
| format | Article |
| id | doaj-art-e0108b7cea1c409f8648bd97fa54bd8b |
| institution | DOAJ |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2018-07-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-e0108b7cea1c409f8648bd97fa54bd8b2025-08-20T03:18:26ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682018-07-01173111910.21294/1814-4861-2018-17-3-11-19540NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCERV. F. Semiglazov0V. V. Semiglazov1G. A. Dashyan2P. V. Krivorotko3V. G. Ivanov4E. K. Zhiltsova5R. M. Paltuev6L. M. Bershtein7T. Yu. Semiglazova8S. S. Yerechshenko9V. V. Klimenko10V. S. Apollonova11A. V. Komyahov12A. A. Bessonov13N.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyMore than 70 % of patients with breast cancer have estrogen-receptor-positive tumors (ER+) and are considered hormone- sensitive. That is why a vast majority of patients with early operable tumors receive adjuvant endocrine therapy. Patients with metastatic ER+ breast cancer also receive hormone therapy as first-line treatment. Patients with ER+/PR+ locally advanced breast cancer including potentially operable cases (cT2N1, cT3N0M0) are still a subject to neoadjuvant chemotherapy in most of the oncology centers in Russia and worldwide. More than 10 years ago, several trials evaluating the efficacy of neoadjuvant endocrine therapy were conducted in the Petrov Research Institute of Oncology (aromatase inhibitors vs tamoxifen, neoadjuvant endocrine therapy vs neoadjuvant chemotherapy, etc.) The primary endpoint was the evaluation of pathologic complete/partial response to therapy and the frequency of breast-conserving surgeries following neoadjuvant treatment. We now represent 10-year long-term follow-up data on comparison of neoadjuvant chemotherapy with neoadjuvant endocrine therapy after retrospective determination of IHC- phenotypes of 239 patients with ER+ breast cancer. The study results show tendency to better 10-year disease-free survival in patients with luminal-A breast cancer who received endocrine therapy compared to neoadjuvant chemotherapy (72.8 % vs 53.9 %, respectively, p=0.062) There were no statistically significant differences in DFS rates among patients with the luminal B breast cancer subtype (41 % vs 40 %) The discovery of biomarkers of potential resistance to endocrine therapy (cycline-dependant kinase activity [cdk 4/6], estrogenreceptor mutation [ESR1], mTOR signaling pathway activity, co-expression of the ER and HER2neu [ER+/ HER2neu3+]) and ways to inhibit the activity of the resistance pathways (palbocyclib, everolimus, etc.) have expanded the armamentarium of endocrine-therapy for not only metastatic and locally-advanced but also operable cases of ER+ breast cancer.https://www.siboncoj.ru/jour/article/view/758breast cancerneoadjuvant endocrine therapyer+ breast cancerhormone-dependent tumors |
| spellingShingle | V. F. Semiglazov V. V. Semiglazov G. A. Dashyan P. V. Krivorotko V. G. Ivanov E. K. Zhiltsova R. M. Paltuev L. M. Bershtein T. Yu. Semiglazova S. S. Yerechshenko V. V. Klimenko V. S. Apollonova A. V. Komyahov A. A. Bessonov NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER Сибирский онкологический журнал breast cancer neoadjuvant endocrine therapy er+ breast cancer hormone-dependent tumors |
| title | NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER |
| title_full | NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER |
| title_fullStr | NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER |
| title_full_unstemmed | NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER |
| title_short | NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER |
| title_sort | neoadjuvant endocrine therapy for patients with estrogen receptor positive breast cancer |
| topic | breast cancer neoadjuvant endocrine therapy er+ breast cancer hormone-dependent tumors |
| url | https://www.siboncoj.ru/jour/article/view/758 |
| work_keys_str_mv | AT vfsemiglazov neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT vvsemiglazov neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT gadashyan neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT pvkrivorotko neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT vgivanov neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT ekzhiltsova neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT rmpaltuev neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT lmbershtein neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT tyusemiglazova neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT ssyerechshenko neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT vvklimenko neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT vsapollonova neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT avkomyahov neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer AT aabessonov neoadjuvantendocrinetherapyforpatientswithestrogenreceptorpositivebreastcancer |